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Background: Self-initiation to antiretroviral treatment (ART) exposes the patient to the risk of 
drug toxicity, poor adherence to treatment, and escalates the development of drug resistance.
Objectives: To determine the sources of antiretroviral (ARV) drugs by unregistered human 
immunodeficiency virus (HIV)-infected patients and the extent of ARV self-medication.
Methods: Simulated clients were used to investigate availability and ARV dispensing practice 
in the private pharmacies in Dar Es Salaam, Tanzania. A total of 480 HIV-infected patients 
qualifying to start ART were interviewed to find out their previous use of ARV drugs prior to 
visiting the HIV clinics. Venous blood (2 mL) was collected from each patient who indicated 
not to have used ARVs in the past (n = 450). Blood samples were analyzed for the presence 
and levels of nevirapine (NVP).
Results: Only 5.1% (23/451) of pharmacies were found stocking ARVs drugs, among which 
4.0% were retail. Drug dispensers in nearly all (15/18) retail pharmacies which stocked ARVs 
were willing to sell ARVs without prescription. Out of 450 enrolled patients, only 2.7% (12) stated 
that they had been receiving ARV drugs from HIV clinics but interrupted the ART treatment 
due to various reasons. From 450 patients, only 10% had quantifiable NVP concentrations in 
the blood, despite stating in an interview that they had not recently used ARVs.
Conclusion: Prior use of ARV drugs outside HIV clinics was rare among patients attending 
those centers. However, the results show that some patients could access and use ARV drugs 
from private pharmacies without undergoing ART eligibility assessment in HIV clinics.
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Introduction
Human immunodeficiency virus (HIV) infection is currently ranked as the number 
two killer disease after malaria in sub-Saharan Africa.1 Most governments in this 
region started providing antiretroviral treatment (ART) in 2005. The World Health 
Organization (WHO) has set criteria for initiation of ART for developing countries, 
which require an HIV-infected patient to have a CD4 count of ,350 cell/µL or acquired 
immune deficiency syndrome (AIDS)-related illnesses regardless of CD4 count.2 
HIV-infected patients are required to attend HIV clinics for assessment to ensure that 
they meet criteria for ART initiation. Patients can then get an antiretroviral (ARV) 
prescription from a clinician so as to access the ARV drugs from HIV clinics. Not going 
through HIV clinics, and self-initiation of ART, exposes the patient to risk of using 
the drugs with contraindicated conditions. In this case, patients also miss important 
information such as consequences of treatment interruptions, management of ARV 
drug toxicities, and advantages of adherence to ART.3–7
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To complement the effort of governments in the provision of 
free ART to all HIV-infected patients in sub-Saharan Africa, the 
private sector also provides ARVs to eligible patients who are 
registered in HIV clinics. Unfortunately, availability of ARVs 
in private pharmacies enhances increased access to ARVs, 
even to those who are not yet assessed and registered to start 
using ARVs. In addition, provision of drugs through private 
drug outlets has been reported to be associated with irrational 
dispensing of important medicines such as antibiotics.8–11 In 
developing countries, many people have been reported to 
initially visit pharmacies to seek medication and medical 
information when they fall sick.9–11 Considering the stigma 
associated with HIV infection, it is highly probable that some 
patients may initially try to access ARVs from pharmacies. 
In this case, patients are not assessed for ART eligibility and 
hence miss adequate counseling on treatment adherence and 
management of ARV drug toxicities.12,13
Therefore, this study was undertaken to determine the 
extent of sourcing and using ARVs without undergoing 
assessment at HIV clinics for ART eligibility. The possibility 
of HIV patients accessing ARVs from private drug outlets 
and ARV drug dispensing practices in private pharmacies is 
hereby reported.
Experimental
Study area
This cross-sectional study involved 451 private pharmacies 
and two HIV clinics at Muhimbili National Hospital and 
Mwanayamala District Hospital. Muhimbili National Hospital 
is one of the few referral hospitals in the country and is the 
biggest hospital in the country. Mwananyamala is a district 
hospital located in the Kinondoni district in Dar Es Salaam. 
The study pharmacies and hospitals are all located in Dar Es 
Salaam, Tanzania. The study took place between January and 
July 2010. A total of 480 HIV-positive outpatients (adults and 
adolescents, both males and females) from the two HIV clinics 
were interviewed. Nurses and counselors of each HIV clinic 
were involved in identification of those patients who were 
assessed by HIV clinicians and found to be eligible to start 
ART on the week when research assistants visited the clinics. 
The patients were selected based on the first-in, first-taken 
principle, as long as each one met the inclusion criteria.
Assessment of ArVs prior to use outside HIV clinics
Patients were interviewed to find out their previous use of 
ARV drugs before visiting the HIV clinic. The inclusion 
criterion for patient recruitment was HIV-infected patient 
qualifying to start ART after undergoing assessment for ART 
initiation. In total, 480 patients were enrolled in the study 
after consenting and meeting other eligibility criteria. Each 
patient who stated not to have used antiretroviral drugs before 
registering at the clinic was requested to allow a phlebotomist 
to collect a single venous blood (2 mL) from his/her arm.
Venous blood was collected from 450 HIV-infected 
patients after they had consented. The samples were 
  centrifuged immediately at 1500 g for 10 minutes, and the 
obtained plasma was kept at −80°C until assay.
The plasma samples were analyzed for concentrations 
of   nevirapine (NVP) using a high performance liquid 
ch  romatography (HPLC) method developed by the authors. 
Details of the method have been published elsewhere.14 The 
levels of NVP were used as an indication of recent use of 
ARV drugs.
Assessment of ArVs dispensing practice  
in private pharmacies
Assessment of ARV drug dispensing practice in private 
pharmacies involved 451 pharmacies, among which, 
51 were wholesale. The pharmacies were selected based 
on accessibility and whether the premises were still active. 
Information on the status of the pharmacies was provided 
by drug regulatory agencies of the Ministry of Health. Data 
collection was done using simulated clients (SC).
The SC posed as a relative of an HIV-infected patient 
whose CD4 count was below 200 cells/µL. The SC stated 
that his relative had been on ART in another town but had 
recently moved to Dar Es Salaam. Then, he asked if there 
was a possibility of buying ARVs from the pharmacy while 
waiting for his relative to be enrolled in another HIV clinic 
in Dar As Salaam. The second SC had an ARV prescription 
claimed to have been written at a private dispensary, but the 
prescription did not have the name of the dispensary, the 
address, or the name of the prescriber. The SC requested 
a combination of stavudine/zidovudine, lamivudine, and 
nevirapine drugs from the pharmacies.
Ethical issues
Verbal and written informed consent was sought from the 
participants. Ethical clearance was granted by the Muhimbili 
University of Health and Allied Sciences (MUHAS) ethics 
committee.
Data analysis
The proportion of HIV-infected patients who had previously 
used ARVs before attending the HIV clinic was determined. 
The proportion of HIV-infected patients who stated not to 
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have used ARVs previously but had a quantifiable level of 
NVP in their blood samples was also determined. The data 
was used to determine the proportion of patients who were 
not naïve to ART. Data obtained from the private community 
pharmacies was used to determine the proportion of premises 
that served as possible sources of ARVs to some patients 
who bypassed HIV clinics.
Results
ArV drug use prior to attending  
HIV clinic
Table 1 describes their demographic characteristics, and it can 
be seen that the majority of the study patients in both clinics 
were female and aged 26–35 years. Blood samples were able 
to be taken from 450 patients after   consenting to participate 
in the study. All regimens used were triple ARV combination 
therapy and contained nevirapine. The combinations which 
were highly recommended as first-line options at that time 
were: AZT (zidovudine) + 3TC (lamivudine) + NVP or 
4dT (stavudine) + 3TC + NVP. However, the treatment 
guidelines have changed and currently the mostly prescribed 
combination is AZT + 3TC + EFV unless the patient is 
woman with childbearing potential.
Out of these patients, only 2.7% (12) acknowledged that 
they had received ARVs from HIV clinics in the past but 
interrupted the treatment due to various reasons including 
lack of fare money to travel to HIV clinics, experiencing drug 
toxicity, and inadequate supply of ARV at the clinics at which 
they were registered. The patients had NVP concentration 
of ,0.05 µg/mL (the limit of quantification of the method 
used).14 Of the 450 blood samples collected from a similar 
number of HIV-infected patients, 10% had quantifiable 
nevirapine concentrations, despite the patients stating that 
they had never used ARVs in the past. The blood samples from 
these patients who claimed to be ART naïve in an interview 
had nevirapine plasma concentrations ranging between 
0.2 and 4.4 µg/mL (median 0.92 µg/mL) (Table 2). Adding 
together those who had interrupted ARV use and those who 
had detectable levels of NVP in blood, made a total of 14% 
(67/480) of the patients who had used ARV drugs, and all 
were presumed to be new patients.
ArV dispensing practice in pharmacies
A total of 451 pharmacies were visited. These included 
400 retail and 51 wholesale pharmacies. Only 5.1% (23/451) 
of the visited pharmacies stocked ARVs, among which about 
1% were wholesale pharmacies. Using an SC technique, it 
was found that 4.5% (18) of the retail pharmacies stocked 
ARVs, and nearly all of them (15/18) were willing to sell the 
drugs to any patient as long as the SC indicated that his patient 
had CD4 counts below 200 cells/µL. The same number of 
pharmacies were willing to dispense ARVs to the SC who had 
a prescription which did not bear the name of the dispensary 
and had no signature of the prescriber.
All the wholesale pharmacies that stocked ARVs (n = 5) 
by that time also dispensed the drugs to patients who pre-
sented ART prescriptions and CD4 count filled forms from 
recognized HIV clinics.
Discussion
This study confirmed by the use of HPLC plasma analysis 
that the majority (90%) of new HIV patients enrolled for ART 
Table 1 Demographic characteristics of the study patients, N = 480
Characteristic N (%)
MLH, N = 408 MNH, N = 72
Gender
M 150 (37) 24 (33)
F 258 (63) 48 (67)
Age (years)
15–25 46 (11.3) 8 (11.1)
26–35 193 (47.3) 29 (40.3)
36–45 114 (27.9) 25 (34.7)
46–55 32 (7.8) 9 (12.5)
56+ 23 (5.7) 1 (1.4)
Education level
No formal school 25 (6.1) 1 (1.4)
Primary school 310 (76) 44 (61.1)
Secondary school 59 (14.5) 17 (23.7)
Post secondary school (certificate) 11 (2.7) 5 (6.9)
College education (diploma) 3 (0.7) 5 (6.9)
Occupation
Not employed 116 (28.5) 16 (22.2)
Self employed 223 (54.7) 32 (44.4)
Employed 69 (16.8) 24 (33.3)
Abbreviations: F, female; M, male; MLH, Mwananyamamala HIV Clinic; MNH, 
Muhimbili HIV Clinic.
Table 2 Proportion of patients in relation to previous drug use 
and ArV drug level obtained in patients who consented to give a 
blood sample (N = 450)
% of patients  
(N)
Obtained NVP plasma 
concentrations,  
μg/mL
Stated to have acquired 
ArV previously from  
HIV clinics
2.7 (12) ,0.05
Stated to have not used 
ArV, despite having NVP  
in their blood samples
10 (45) 0.25–4.40
Total 12.7 (67)
Abbreviations: ARV, antiretoviral; HIV, human immunodeficiency virus; NVP, nevirapine.
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women who used NVP-based highly active ART with CD4 
counts higher than 350 cells/µL.19 ART interruption exposes 
the HIV patient to risk of developing drug resistance. Proper 
use of antiretroviral therapy in HIV-1 infection enhances 
treatment outcomes and immunological recovery.18
Limitations
The small sample size of pharmacies which were stocking 
ARVs is a limitation of this study. The study was conducted 
in only one region (Dar es Salaam), where the Ministry of 
Health and medical and drug regulatory agencies are located. 
This may have an influence on the practice of HIV clinics 
and the private pharmacies.
The study involved only two HIV clinics, both of which 
have a good number of trained HIV health workers involved 
in the care and treatment of HIV patients. Furthermore, a 
great deal of community sensitization campaigns on effective 
use of HIV clinics has been conducted in Dar es Salaam, 
and many people have timely access to the information due 
to presence of mass communication media. It is possible 
that the   magnitude of the problem could be higher in the 
up-country. It is therefore recommended that a similar study 
be conducted in other regions by involving a bigger number 
of HIV clinics and patients.
Conclusion
The findings of this study indicate that the majority of the 
patients were naïve to ART prior to visiting HIV clinics. 
Therefore, it can be extrapolated that the use of ARV drugs 
outside HIV clinics was rare among patients visiting these 
centers. However, some patients could access and use ARVs 
from private pharmacies without undergoing ART eligibility 
assessment in HIV clinics, thus highlighting the likely 
  setbacks in involving private pharmacies in the provision of 
ARV drugs in the HIV programs of developing countries.
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initiation were indeed ARV naïve. Only 2.7% of the patients 
acknowledged that they had previously obtained the ARVs 
from HIV clinics but interrupted the treatment due to   various 
reasons including drug toxicity and inability to visit the 
clinics. The blood samples from 45 (10%) patients   purported 
to be ART naïve had nevirapine plasma concentrations 
ranging between 0.2 and 4.4 µg/mL (median 0.92 µg/mL) 
(therapeutic range of nevirapine is 2–5 µg/mL),15,16 although 
they stated in an interview that they had not recently used 
ARV drugs. This implies that such patients had been self-
treating with ARVs without undergoing pre-ART assessment 
at HIV clinics.
In this study, 2.7% patients stated that they had interrupted 
the ARV medication due to various reasons. ART defaulters 
do resume HIV clinic visits with a deteriorated health condi-
tion and have been reported to end up with poor treatment 
outcomes.6,17 Better treatment prognosis is associated with 
adherence to treatment and naivety to ARV drugs.5,18 Those 
HIV-infected patients who delay visiting the clinics are likely 
to suffer the risk of starting ART when they have too low 
CD4 count to sustain cure.7
This study has shown that pharmacies stocking ARVs 
were willing to sell the drugs to patients/clients who claimed 
to have CD4 count , 200 cells/µL. These pharmacies 
also sold ARVs to patients who did not have genuine ART 
  prescriptions. The possibility of obtaining ARVs from 
  pharmacies without providing a prescription from an HIV 
clinic enhances the behavior of self-medication with ARV 
drugs. The authors found out that even some of the wholesale 
pharmacies were practicing retail activities. Drug provision 
in developing countries is often poorly regulated, and some 
of the drug outlets dispense drugs illegally.8–11 This present 
study has shown that there was irrational dispensing of ARV 
drugs in the private pharmacies. Patients could just mention 
their sero-status and obtain ARV drugs without having a 
genuine ARV prescription written by a prescriber working 
at the HIV clinics. Availability of even a single center with 
unregulated ARV drug provision creates a loophole for 
those patients who would like to bypass HIV clinics. This 
in turn has a negative impact on the roll-out of an ART 
program and affects the government’s political will to curb 
the pandemic.
Dangers of bypassing an HIV clinic assessment for ART 
initiation include discontinuation of the treatment after 
experiencing drug toxicity17 or using the drugs with con-
traindicated conditions. For instance, it was recently reported 
that hypersensitivity reactions affected some HIV-infected 
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